Evidence map›Paper›PMID 30609798›Full record

ArticleMolecules (Basel, Switzerland)2019

(-)-Epigallocatechin-3-Gallate Decreases Osteoclastogenesis via Modulation of RANKL and Osteoprotegrin.

Shih-Tse Chen, Lin Kang, Chau-Zen Wang, Peng-Ju Huang, Hsuan-Ti Huang, Sung-Yen Lin, Shih-Hsiang Chou, Cheng-Chang Lu, Po-Chih Shen, Yi-Shan Lin and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Tea consumption and risk of fractures: an updated meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019
    Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Journal of materials chemistry. B · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Antioxidants (Basel, Switzerland) · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Shih-Tse ChenDepartment of Psychiatry, National Taiwan University Hospital Hsin-Chu Branch, Hsin Chu 30059, Taiwan. chenshihtse@yahoo.com.tw.
Lin KangDepartment of Obstetrics and Gynecology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan. kanglin@mail.ncku.edu.tw.
Chau-Zen WangOrthopaedic Research Center, Kaohsiung Medical University, Kaohsiung 80701, Taiwan. czwang@kmu.edu.tw.
Peng-Ju HuangDepartment of Orthopedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80701, Taiwan. roger01@ms4.hinet.net.
Hsuan-Ti HuangDepartment of Orthopedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80701, Taiwan. hthuang@kmu.edu.tw.
Sung-Yen LinOrthopaedic Research Center, Kaohsiung Medical University, Kaohsiung 80701, Taiwan. tony8501031@gmail.com.
Shih-Hsiang ChouDepartment of Orthopedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80701, Taiwan. stanelychou@yahoo.com.tw.
Cheng-Chang LuDepartment of Orthopedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80701, Taiwan. cclu0880330@gmail.com.
Po-Chih ShenDepartment of Orthopedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80701, Taiwan. shenporch@gmail.com.ORCID 0000-0001-5185-5584
Yi-Shan LinOrthopaedic Research Center, Kaohsiung Medical University, Kaohsiung 80701, Taiwan. 327lin@gmail.com.
Chung-Hwan ChenOrthopaedic Research Center, Kaohsiung Medical University, Kaohsiung 80701, Taiwan. hwan@kmu.edu.tw.ORCID 0000-0001-8941-4792
Kaohsiung Medical University · TWNational Cheng Kung University Hospital · TWNational Taiwan University Hospital · TW

Funding

Kaohsiung Medical University KMU-DK105009Kaohsiung Medical University KMU-TP105B10Kaohsiung Medical University Hospital KMUH106-6R51Minister of Science and Technology of Taiwan MOST 104-2314-B-037-032-MY3National Health Research Institutes NHRI-EX101-9935EINational Science Council NSC 94-2314-B-037 -021 -
6 · The paper itself

Abstract

Osteoporosis is the second most common epidemiologic disease in the aging population worldwide. Previous studies have found that frequent tea drinkers have higher bone mineral density and less hip fracture. We previously found that (-)-epigallocatechin gallate (EGCG) (20⁻100 µmol/L) significantly suppressed receptor activator of nuclear factor-kB ligand (RANKL)-induced osteoclastogenesis and pit formation via inhibiting NF-κB transcriptional activity and nuclear transport of NF-κB in RAW 264.7 cells and murine primary bone marrow macrophage cells. The most important regulation in osteoclastogenesis is the receptor activator of nuclear factor-kB/RANKL/osteoprotegrin (RANK/RANKL/OPG) pathway. In this study, we used the coculture of RAW 264.7 cells and the feeder cells, ST2, to evaluate how EGCG regulated the RANK/RANKL/OPG pathway in RAW 264.7 cells and ST2 cells. We found EGCG decreased the RANKL/OPG ratio in both mRNA expression and secretory protein levels and eventually decreased osteoclastogenesis by TRAP (+) stain osteoclasts and TRAP activity at low concentrations-1 and 10 µmol/L-via the RANK/RANKL/OPG pathway. The effective concentration can be easily achieved in daily tea consumption. Taken together, our results implicate that EGCG could be an important nutrient in modulating bone resorption.

Indexed as

AnimalsCatechinCell CycleCell LineCell SurvivalGene ExpressionMiceOsteoclastsOsteogenesisOsteoprotegerinRANK LigandRAW 264.7 CellsRNA, MessengerTartrate-Resistant Acid PhosphataseAcp5 protein, mouseCatechinepigallocatechin gallateOsteoprotegerinRANK LigandRNA, MessengerTartrate-Resistant Acid PhosphatasecatechinEGCGosteoclastosteoclastogenesisRANK/RANKL/OPGRAW 264.7 cells

Identifiers

PMID30609798
PMCPMC6337469
OpenAlexW2907689514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.